NSE · WANBURY · Pharmaceuticals
Wanbury Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹166 Cr with net profit ₹3 Cr — a 1.96% net margin, versus 13.19% the period before.
Shareholding
As of 2026-06-30
- Promoter43.02%
- Public56.03%
- FII0.89%
- DII0.06%
17,174 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.22× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #56 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,48,028 Cr | 35.46 | 5.36 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,13,227 Cr | 23.19 | 4.18 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,11,186 Cr | 31.07 | 3.22 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,258 Cr | 96.25 | 19.94 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹98,075 Cr | 30.44 | 2.57 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹97,239 Cr | 25.72 | 2.56 | 9.25% | 10.7% |
| Lupin Limited | ₹95,939 Cr | 16.11 | 4.26 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹95,000 Cr | 44.53 | 5.82 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,185 Cr | 21.85 | 6.48 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹63,949 Cr | 28.06 | 4.62 | 16.66% | 14.31% |
| Wanbury Limited(this company) | ₹782 Cr | 18.2 | 10.06 | 51.51% | 6.83% |
AI analysis
AI-generated · google/gemini-2.5-flashWanbury Limited is listed on the Indian markets with a market capitalization of Rs 1161 Cr. The one-year high for the share price was Rs 358.85 and the one-year low was Rs 161.5.
Positives
- +Return on capital employed (ROCE) is 27.98%, indicating efficient use of capital.
- +Return on equity (ROE) is 20%, suggesting good profitability relative to shareholder investment.
Negatives
- −Promoter shareholding has 86.69% of shares pledged, which could be a risk.
- −The debt-to-equity ratio is 3.38, indicating a high reliance on debt financing.
- −Promoter holding decreased from 76.76% in June 2019 to 43.0161% in June 2026.
- −The stock is under ST-ASM · ASM 1 surveillance, which may indicate increased monitoring by regulators.
- −No quarterly results have been disclosed since June 2025.
Financial Performance
The company reported revenue of Rs 603.01 Cr. Annual revenue for March 2025 was Rs 172 Cr with a net profit of Rs 20.26 Cr. Quarterly revenue for June 2025 stood at Rs 163.18 Cr, generating a net profit of Rs 13.49 Cr.
Profitability & Returns
Wanbury Limited reported an EPS of Rs 9.32. The return on equity (ROE) is 20% and the return on capital employed (ROCE) is 27.98%. The trailing twelve-month P/E ratio is 25.18.
Balance Sheet
The company has a book value of Rs 16.26. The debt-to-equity ratio is 3.38, indicating a relatively high level of debt compared to equity.
Ownership & Pledges
As of June 2026, promoter holding is 43.0161%, with 86.69% of these shares pledged.
Regulatory & Surveillance
The stock is currently under ST-ASM · ASM 1 surveillance, with 'ST-ASM' listed as a measure.
Data as of — price: 2026-09-18 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.